Vanda Pharmaceuticals Faces Setback as FDA Denies Hetlioz Label Expansion
Wednesday, 6 March 2024, 12:23
Vanda Pharmaceuticals Faces Stock Decline
Vanda Pharmaceuticals (VNDA) is grappling with a sharp decline in its stock value after the FDA decision.
FDA Denies Hetlioz Label Expansion
The FDA's rejection of the label expansion for Vanda's sleep disorder therapy Hetlioz has sent shockwaves through the pharmaceutical industry.
- Impact on Stock Price: Vanda's stock plummets amid uncertainties arising from the FDA decision.
- Investor Concerns: Stakeholders express worries over the company's future growth prospects and market stability.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.